WAVE.V =MCap C$ 9 Million / 5x Cancer Drugs approved in Europe ,market launch expected next Quarter / 2 additional BIG Cancer Drugs awaiting approval in US and Europe expected to be approved in Q4 2020 / Another 6 Cancer Drugs acquired early this month / Its also a covid 19 gem too = UNDISCOVERED stock with MASSIVE Upside Potential could be a 20 Bagger or more ....
The brands represented by these six generic products, referred to by the Company as WAV-103, WAV-104, WAV-105, WAV-106, WAV-107 and WAV-108, had combined sales of more than $3 billion USD in 2019.
WAV-101 is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications. Currently there is no marketed generic version for this product in the United States, and the brand generates yearly revenue of over $1 billion USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
WAV-102 is an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. Currently there is no marketed generic for this product and the brand generates yearly revenue of over $800 million USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.